As Executive Director – Strategy & Operations @ Bristol Myers Squibb, Bill currently leads a team that acts as advocate, internal consultant, financial advisor and project management officer for key strategic initiatives for BMS’s - Small Molecule Drug Discovery efforts, a multi-site international group exceeding 1000 scientists.
Bill brings a unique background & perspective to this operations role.
The first 15 years of his career with Bayer, Bill contributed to and lead several successful research programs. In addition to this portfolio responsibilities, Bill was involved in the re-examination & redefinition of several global R&D processes, including a fundamental transformation of early drug candidate selection process - targeting increased Phase 1 success; a global harmonization of research practices & roles allowing for the creation of a web-based portfolio management tool; and deployment of electronic notebooks in the US.
With this passion for fundamental transformation with appropriate risk taking, Bill brings a tremendous energy to his Strategy & Operations role @ BMS. His responsibilities involve ensuring a continuous flow of new strategies and reengineering opportunities that maximize Research’s operational efficiency and ability to innovate. Notable transformations include a novel and highly successful in-source model for drug candidate purification; leadership of the company’s first open office deployment; advancing laboratory designs and leveraging electronic notebooks to increase safety awareness. With all transformations, detailed change management programs are developed & executed to ensure each initiative yields its maximal impact. Individual projects have delivered from $ 100 k to $ 5 million in annual savings and been recognized both internally and externally, including the 2012 Bio IT World Judges Prize, and an article on Selective Integration in the company’s annual report; and provisional membership to the NATIONAL ACADEMIES OF SCIENCES-ENGINEERING-MEDICINE.